Is EC 805-439-9 Safe in Breastfeeding
Question
I am a breastfeeding mother and i want to know if it is safe to use EC 805-439-9? Is EC 805-439-9 safe for nursing mother and child? Does EC 805-439-9 extracts into breast milk? Does EC 805-439-9 has any long term or short term side effects on infants? Can EC 805-439-9 influence milk supply or can EC 805-439-9 decrease milk supply in lactating mothers?
EC 805-439-9 lactation summary
- DrLact safety Score for EC 805-439-9 is 3 out of 8 which is considered Low Risk as per our analyses.
- A safety Score of 3 indicates that usage of EC 805-439-9 may cause some minor side effects in breastfed baby.
- Our study of different scientific research indicates that EC 805-439-9 may cause moderate to no side effects in lactating mother.
- Most of scientific studies and research papers declaring usage of EC 805-439-9 low risk in breastfeeding are based on normal dosage and may not hold true for higher dosage.
- While using EC 805-439-9 We suggest monitoring child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
Answer by Dr. Ru: About EC 805-439-9 usage in lactation
Used in the treatment of hepatitis C, usually in combination with other antivirals. Since the last update we have not found published data on its excretion in breast milk. Its pharmacokinetic data (slightly elevated molecular weight and very high percentage of plasma protein binding) make it very unlikely that significant amounts will pass into milk, so that although there is disagreement (Thompson 2016), other experts believe that treatment with EC 805-439-9, on its own or in combination with ombitasvir, paritaprevir and ritonavir or with sofosbuvir is not contraindicated during breastfeeding (LactMed 2016, Spera 2016). See below the information of these related products:
Answer by DrLact: About EC 805-439-9 usage in lactation
EC 805-439-9 has not been studied in nursing mothers being treated for hepatitis C infection. Because it is greater than 99.5% bound to maternal plasma proteins, amounts in breastmilk are likely to be very low. If EC 805-439-9 used alone or in combination with sofosbuvir or with ombitasvir, paritaprevir and ritonavir (Viekira Pak) is required by the mother, it is not a reason to discontinue breastfeeding.[1] Some sources recommend against breastfeeding when EC 805-439-9 is used with ribavirin. Hepatitis C is not transmitted through breastmilk[2][3] and breastmilk has been shown to inactivate hepatitis C virus (HCV).[4][5] However, the Centers for Disease Control recommends that mothers with HCV infection should consider abstaining from breastfeeding if their nipples are cracked or bleeding. It is not clear if this warning would apply to mothers who are being treated for hepatitis C. Infants born to mothers with HCV infection should be tested for HCV infection; because maternal antibody is present for the first 18 months of life and before the infant mounts an immunologic response, nucleic acid testing is recommended.[2][3]
Alternate Drugs
Zanamivir(Safe)
Daclatasvir(Low Risk)
Emtricitabine(Safe)
Zidovudine(Low Risk)
Dasabuvir(Low Risk)
Efavirenz(Unsafe)
Didanosine(Unsafe)
Tenofovir(Safe)
Saquinavir(Unsafe)
Ribavirin(Low Risk)
Abacavir(Safe)
Valganciclovir(Low Risk)
Ritonavir(Unsafe)
Oseltamivir(Safe)
Ganciclovir(Low Risk)
Amantadine(Low Risk)
Nevirapine(Low Risk)
Velpatasvir(Low Risk)
Nelfinavir(Unsafe)
Penciclovir(Safe)
Simeprevir(Low Risk)
Famciclovir(Low Risk)
Sofosbuvir(Low Risk)
Acyclovir(Safe)
Lamivudine(Safe)
Ledipasvir(Low Risk)
Indinavir(Unsafe)
Ombitasvir(Low Risk)